HH

Harte Hanks, Inc.

HHSIndustrialsNASDAQ

Conglomerates · Last scanned Oct 24, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$159.6M
-13.9% YoY
Net Income
-$811,000
+97.3% YoY
EBITDA
$6.6M
-44.9% YoY
Free Cash Flow
$4.5M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Oct 20▲ RSI OversoldRSI 25.4, below 30, stock may be oversold
Oct 19CONFIRMED▲ RSI OversoldRSI 19.6, below 30, stock may be oversold
About Harte Hanks, Inc.

Harte Hanks, Inc. operates as a customer experience company in the United States and internationally. The $29.2M market capitalization puts HHS squarely in micro-cap range for its industry. It operates through three segments: Revenue Solutions, Customer Care, and Fulfillment and Logistics.

Where HHS stands vs its 150-day and 200-day moving averages

As of the October 20, 2026 close, HHS finished 41.56% above its 150-day moving average ($3.08) and 43.89% above its 200-day moving average ($3.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is HHS overbought or oversold?

At the October 20, 2026 close, HHS's RSI(14) was 25.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$29.2M
Fwd P/E3.66
EPS$-0.72
Beta0.17
52W Change+13.3%
Dividend Yield0.00%
ROE-30.4%
Analysis

On the balance sheet, HHS has $5.2M in cash with $24.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $4.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -30.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $206.3M (2022) to $159.6M (2025), a 23% decline worth watching.

HHS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Harte Hanks, Inc. and its sector.

Links
More Industrials stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms